PL3137052T3 - Leczenie lub zapobieganie brodawce łojotokowej z zastosowaniem artemizyniny i jej pochodnych - Google Patents
Leczenie lub zapobieganie brodawce łojotokowej z zastosowaniem artemizyniny i jej pochodnychInfo
- Publication number
- PL3137052T3 PL3137052T3 PL15717920T PL15717920T PL3137052T3 PL 3137052 T3 PL3137052 T3 PL 3137052T3 PL 15717920 T PL15717920 T PL 15717920T PL 15717920 T PL15717920 T PL 15717920T PL 3137052 T3 PL3137052 T3 PL 3137052T3
- Authority
- PL
- Poland
- Prior art keywords
- artemisinin
- prevention
- derivatives
- treatment
- seborrheic keratosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14166277 | 2014-04-28 | ||
| PCT/EP2015/059104 WO2015165856A1 (en) | 2014-04-28 | 2015-04-27 | Treatment or prevention of seborrheic keratosis using artemisinin and derivatives thereof |
| EP15717920.1A EP3137052B1 (en) | 2014-04-28 | 2015-04-27 | Treatment or prevention of seborrheic keratosis using artemisinin and derivatives thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3137052T3 true PL3137052T3 (pl) | 2019-02-28 |
Family
ID=50624467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15717920T PL3137052T3 (pl) | 2014-04-28 | 2015-04-27 | Leczenie lub zapobieganie brodawce łojotokowej z zastosowaniem artemizyniny i jej pochodnych |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9907782B2 (pl) |
| EP (1) | EP3137052B1 (pl) |
| JP (1) | JP6487459B2 (pl) |
| KR (1) | KR20160145818A (pl) |
| CN (1) | CN106456600B (pl) |
| AU (1) | AU2015252207B2 (pl) |
| BR (1) | BR112016024916A2 (pl) |
| CA (1) | CA2945646C (pl) |
| DK (1) | DK3137052T3 (pl) |
| ES (1) | ES2694623T3 (pl) |
| HR (1) | HRP20181981T1 (pl) |
| IL (1) | IL247909A0 (pl) |
| MX (1) | MX367732B (pl) |
| PL (1) | PL3137052T3 (pl) |
| PT (1) | PT3137052T (pl) |
| RU (1) | RU2702347C2 (pl) |
| SG (1) | SG11201607734PA (pl) |
| SI (1) | SI3137052T1 (pl) |
| WO (1) | WO2015165856A1 (pl) |
| ZA (1) | ZA201606837B (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3824895A1 (en) * | 2019-11-19 | 2021-05-26 | Johnson & Johnson Consumer Inc. | Compositions and methods for treating the eye |
| WO2024112391A1 (en) * | 2022-11-23 | 2024-05-30 | Timber Pharmaceuticals, Inc. | Compositions for local delivery of drug actives |
| WO2025173801A1 (en) * | 2024-02-14 | 2025-08-21 | L'oreal | Cosmetic process using microneedles |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2712861C2 (de) | 1977-03-21 | 1986-02-27 | Schering AG, 1000 Berlin und 4709 Bergkamen | 17-Acetoxy-6-chlor-15β-hydroxy-1α,2α-methylen-4,6-pregnadien-3,20-dion, Verfahren zu seiner Herstellung und dieses enthaltende Arzneimittel |
| US4916204A (en) * | 1987-07-31 | 1990-04-10 | Massachusetts Institute Of Technology | Pure polyanhydride from dicarboxylic acid and coupling agent |
| JPH03170422A (ja) | 1989-11-22 | 1991-07-24 | Dermatologic Res Corp | 皮膚疾患の治療法 |
| US7381427B2 (en) | 2001-02-09 | 2008-06-03 | Mickey Miller | Seborrheic keratosis treatment |
| WO2005048912A2 (en) * | 2003-11-19 | 2005-06-02 | Vecta Ltd. | Methods and compositions for the treatment of helicobacter pylori-associated diseases using endoperoxide bridge-containing compounds |
| JP5119155B2 (ja) * | 2005-10-20 | 2013-01-16 | エピフアルマ・アクチエンゲゼルシヤフト | アルテミシニン及びその誘導体を使用する良性色素性ホクロ（母斑）の処置及び予防 |
| US8193376B2 (en) * | 2007-01-01 | 2012-06-05 | Bioderm Research | Artemisinin derivatives with natural amino acids, peptides, and amino sugars for the treatment of infection and topical condition in mammals |
| KR100795515B1 (ko) * | 2007-01-11 | 2008-01-16 | 바이오스펙트럼 주식회사 | 아테미시닌을 포함하는 피부 미백용 조성물 |
| WO2009033494A1 (en) * | 2007-09-10 | 2009-03-19 | Dafra Pharma N.V. | 1- or 2-substituted artemisinin derivatives for increasing the in vivo biological activity of biologically active compounds |
| US9402823B2 (en) | 2010-12-17 | 2016-08-02 | Leo Laboratories Limited | Ingenols for treating seborrheic keratosis |
| KR20120085953A (ko) | 2011-01-25 | 2012-08-02 | 원영두 | 피부미용제 및 그 제조방법 |
| US9814659B2 (en) | 2012-04-02 | 2017-11-14 | Johnson & Johnson Consumer Inc. | Methods of lightening the skin |
-
2015
- 2015-04-27 PL PL15717920T patent/PL3137052T3/pl unknown
- 2015-04-27 ES ES15717920.1T patent/ES2694623T3/es active Active
- 2015-04-27 WO PCT/EP2015/059104 patent/WO2015165856A1/en not_active Ceased
- 2015-04-27 SI SI201530505T patent/SI3137052T1/sl unknown
- 2015-04-27 BR BR112016024916A patent/BR112016024916A2/pt not_active Application Discontinuation
- 2015-04-27 MX MX2016013114A patent/MX367732B/es active IP Right Grant
- 2015-04-27 RU RU2016146373A patent/RU2702347C2/ru active
- 2015-04-27 EP EP15717920.1A patent/EP3137052B1/en active Active
- 2015-04-27 CN CN201580022768.1A patent/CN106456600B/zh not_active Expired - Fee Related
- 2015-04-27 JP JP2016562748A patent/JP6487459B2/ja not_active Expired - Fee Related
- 2015-04-27 AU AU2015252207A patent/AU2015252207B2/en not_active Ceased
- 2015-04-27 SG SG11201607734PA patent/SG11201607734PA/en unknown
- 2015-04-27 CA CA2945646A patent/CA2945646C/en active Active
- 2015-04-27 US US15/305,516 patent/US9907782B2/en active Active
- 2015-04-27 DK DK15717920.1T patent/DK3137052T3/da active
- 2015-04-27 PT PT15717920T patent/PT3137052T/pt unknown
- 2015-04-27 HR HRP20181981TT patent/HRP20181981T1/hr unknown
- 2015-04-27 KR KR1020167033065A patent/KR20160145818A/ko not_active Ceased
-
2016
- 2016-09-19 IL IL247909A patent/IL247909A0/en active IP Right Grant
- 2016-10-05 ZA ZA2016/06837A patent/ZA201606837B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201606837B (en) | 2022-05-25 |
| CN106456600B (zh) | 2020-08-04 |
| EP3137052B1 (en) | 2018-08-29 |
| AU2015252207A1 (en) | 2016-10-06 |
| EP3137052A1 (en) | 2017-03-08 |
| US20170035727A1 (en) | 2017-02-09 |
| IL247909A0 (en) | 2016-11-30 |
| CN106456600A (zh) | 2017-02-22 |
| SG11201607734PA (en) | 2016-11-29 |
| AU2015252207B2 (en) | 2019-09-12 |
| US9907782B2 (en) | 2018-03-06 |
| CA2945646C (en) | 2020-12-15 |
| PT3137052T (pt) | 2018-11-30 |
| JP2017516761A (ja) | 2017-06-22 |
| MX2016013114A (es) | 2017-02-14 |
| CA2945646A1 (en) | 2015-11-05 |
| BR112016024916A2 (pt) | 2017-08-15 |
| MX367732B (es) | 2019-09-04 |
| WO2015165856A1 (en) | 2015-11-05 |
| NZ724402A (en) | 2020-11-27 |
| RU2016146373A3 (pl) | 2018-11-14 |
| DK3137052T3 (da) | 2019-01-02 |
| ES2694623T3 (es) | 2018-12-26 |
| HRP20181981T1 (hr) | 2019-01-25 |
| JP6487459B2 (ja) | 2019-03-20 |
| SI3137052T1 (sl) | 2019-01-31 |
| RU2702347C2 (ru) | 2019-10-08 |
| RU2016146373A (ru) | 2018-05-28 |
| KR20160145818A (ko) | 2016-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL252839A0 (en) | Treatment of boils | |
| ZA201605639B (en) | Hppd variants and methods of use | |
| GB201701673D0 (en) | Methods of well treatment | |
| SG11201803213XA (en) | Glycan-interacting compounds and methods of use | |
| HUE061672T2 (hu) | Glikán-interakcióban lévõ vegyületek és felhasználási módszerek | |
| LT3089971T (lt) | Junginiai ir panaudojimo būdai | |
| IL282482A (en) | Variants of protoxin-II and methods of use | |
| ZA201606243B (en) | Hppd variants and methods of use | |
| IL290855A (en) | Treatment methods using vitamin d | |
| PL3183003T3 (pl) | SPOSOBY ZAPOBIEGANIA l/LUB LECZENIA ZAKAŻENIA | |
| IL247116B (en) | Compositions and methods for treating and preventing macular degeneration | |
| IL254599B (en) | Variants of protoxin-ii and methods of use | |
| GB201413530D0 (en) | Treatment and prevention of malaria | |
| SG11201605915WA (en) | Furo-3-carboxamide derivatives and methods of use | |
| GB201416832D0 (en) | Methods of treatment | |
| ZA201606450B (en) | Compounds and their methods of use | |
| SG11201705889VA (en) | Prevention or Treatment of Uratic or Gouty Diseases | |
| ZA201606837B (en) | Treatment or prevention of seborrheic keratosis using artemisinin and derivatives thereof | |
| IL251135A0 (en) | A method for the synthesis of hydroxy-triglycerides and their use for the prevention and treatment of diseases | |
| GB201412010D0 (en) | Treatment of hypertransaminasemia | |
| GB201512139D0 (en) | Methods of treatment | |
| EP3188744A4 (en) | Methods for treatment and prevention of vascular disease | |
| EP3104940A4 (en) | Compositions and methods for the prevention and/or treatment of schistosomiasis | |
| GB201403697D0 (en) | Compounds and methods of use | |
| GB2532447B (en) | Treatment of Contaminated Land |